CTOs on the Move

Ambrx

www.ambrx.com

 
Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop next generation antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. Ambrx is advancing a focused portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications. Specifically, ARX517, its proprietary antibody-drug conjugates (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. Ambrx spun out of The Scripps Research Institute in 2003 and has several other product candidates involving ADCs and other aspects of Ambrx`s protein engineering technology.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.ambrx.com
  • 10975 North Torrey Pines Road
    La Jolla, CA USA 92037
  • Phone: 858.875.2400

Executives

Name Title Contact Details

Funding

Ambrx raised $45M on 08/05/2016
Ambrx raised $200M on 11/09/2020

Similar Companies

Arkios BioDevelopment Intl

Arkios BioDevelopment Intl is a Virginia Beach, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ProtonDx

Because your organisation needs certainty when testing for Covid-19

Locus Fermentation Solutions

Locus Fermentation Solutions is the the accelerator company for Locus Agricultural Solutions and Locus Bio-Energy Solutions, LLC.

Kronos Bio

Kronos Bio is clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes by targeting dysregulated transcription. Our proprietary product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks (TRNs) through which they drive oncogenic activity.

KalVista Pharmaceuticals

KalVista is a clinical stage pharmaceuticals company focused on the discovery, development, and commercialization of small molecule protease inhibitors.